STOCK TITAN
  1. Home
  2. News
  3. CNTG

Centogene NV - CNTG STOCK NEWS

Welcome to our dedicated news page for Centogene NV (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene NV.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Centogene NV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Centogene NV's position in the market.

News
CENTOGENE Receives Nasdaq Non-Compliance Notice
Rhea-AI Summary
Centogene N.V. (CNTG) received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement. The company's common shares listed on Nasdaq fell below US$1.00 for 30 consecutive business days. Centogene has 180 days to regain compliance by maintaining a bid price of at least US$1.00 per share for 10 consecutive business days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
News
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
Rhea-AI Summary
Centogene N.V. extends partnership with Takeda to provide efficient diagnosis for Lysosomal Storage Disorders globally, emphasizing rapid and reliable diagnostics for diseases like Fabry disease, Gaucher disease, and Hunter syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
Rhea-AI Summary
CENTOGENE N.V. announces rare findings on pre-TCRα deficiency, highlighting the prevalence of partial forms over complete deficiency. The study sheds light on the impact on human immunity and potential noncanonical pathways for T cell development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
News
CENTOGENE Explores Strategic Alternatives
Rhea-AI Summary
Centogene N.V. (CNTG) announces exploration of strategic alternatives to enhance long-term value creation. The company aims to leverage its position as a world leader in rare disease diagnostics and pharma services. Management and the Supervisory Board are collaborating to evaluate options for sustainable growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
News
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
Rhea-AI Summary
Centogene N.V. (CNTG) received a staff determination letter from Nasdaq regarding potential delisting due to non-compliance with the minimum USD $15 million Market Value of Publicly Held Shares requirement. However, this will not immediately result in the suspension or delisting of the company's securities. The company plans to request a hearing before a Hearings Panel to address the issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
News
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
Rhea-AI Summary
CENTOGENE N.V. (CNTG) and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine have announced a strategic research collaboration to accelerate and de-risk drug discovery and clinical development for rare disease patients. The collaboration aims to leverage the CENTOGENE Biodatabank, containing over 70 million unique genetic variants collected from more than 800,000 patients from over 120 countries, to discover and validate novel genetic and biochemical targets for future development of rare disease therapies. The partnership will integrate multiomics and bioinformatics to analyze the diverse data and improve patient health outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
none
News
CENTOGENE Receives French Research Tax Credit Accreditation
Rhea-AI Summary
Centogene N.V. (CNTG) has been recognized by the French Ministry of Higher Education and Research as a qualified organization to support partners conducting R&D projects in France, enabling eligible research-based companies to claim tax relief on 30% of all costs incurred in R&D activities outsourced to CENTOGENE. This accreditation will lower overall R&D costs and support current and future partners in generating novel insights and delivering data-driven, life-changing answers to rare and neurodegenerative disease patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
-
News
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) have announced a collaboration to accelerate research on genetic risk factors associated with Parkinson’s disease (PD), specifically targeting the role of variants in the GBA gene. The aim is to establish a deeper understanding of the relationship between specific GBA gene variants and PD, leveraging CENTOGENE’s expertise in rare genetic and neurodegenerative diseases and MJFF’s extensive expertise and resources. PD is a devastating neurodegenerative disease affecting over 10 million people worldwide, with many cases being linked to genetic factors. The research project will draw on diverse multiomic data in the CENTOGENE Biodatabank, which currently contains more than 800,000 patients representing over 120 highly diverse countries, including over 15,000 Parkinson’s disease datasets from the Company’s ROPAD Study, the world’s largest observational study on PD genetics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
CENTOGENE Announces Preliminary Full Year 2023 Revenue
Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) announced preliminary unaudited revenue for full year 2023 between approximately €48.5 million and €49.0 million, reflecting a growth rate over 2022 in the mid-single digits. They strengthened their diagnostic portfolio, launched additional data and wet lab solutions, and expanded their partnership model with a new joint venture in Saudi Arabia. However, they experienced a lag in Pharma program timelines, impacting their full year 2023 Pharma segment revenue. Heading into 2024, their Pharma order book is set to hit new record levels, with extended relationships with existing biopharma partners and collaborations with 10 new partners.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
News
CENTOGENE Announces Voting Results of Extraordinary General Meeting
Rhea-AI Summary
Centogene N.V. (Nasdaq: CNTG) announced the voting results of the Company’s Extraordinary General Meeting, including the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2022, all passed by the requisite majority.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
none
Stock CNTG logo
Centogene NV

Nasdaq:CNTG

CNTG Rankings

#5290 Ranked by Market Cap
#1218 Ranked by Stock Gains
N/A Ranked by Dividends

CNTG Stock Data

15.48M
9.60M
2.73%
65.22%
0.04%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Germany
Rostock

About CNTG

centogene is a worldwide leader in the field of genetic diagnostic testing for rare hereditary diseases, with a broad test portfolio covering over 2800 genes, biochemical tests, biomarker tests, clinical whole exome sequencing and whole genome sequencing. centogene’s mission is to support medical professionals with in-depth medical expertise in order to diagnose early the cause of the patients’ symptoms. analyzing samples from all over the world allows centogene to constantly expand its unique portfolio resulting in the largest systematic documentation of genetic results, centomd®. this mutation database integrates genetic and clinical information, enabling the highest quality, knowledge-based genetic testing and biomarker development. in addition to offering diagnostic services for individual patients, centogene is a pivotal partner to some of the most respected names in the industry. imprint centogene ag is a stock corporation ('aktiengesellschaft') incorporated under the